Featured Articles

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | December 2018

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | October 25, 2018

Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Department of Health and Human Services Adults and Adolescents Antiretroviral Guidelines Panel* Classifies a Fixed-Dose Combination Product of Bictegravir/Tenofovir Alafenamide/Emtricitabine as One of the Recommended Initial Regimens for Most People with HIV
AIDSinfo |  March 27, 2018
Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury
NASTAD Release: ADAP Formulary Database
HIV/AIDS Update- Prezista (darunavir) labeling changes
The 17th Annual HIV Drug Guide
Positively Aware, Test Positive Aware Network
News Updates

Baseline genotype testing at HIV diagnosis not cost-effective

Healio | May 13, 2019

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

NIH | May 9, 2019

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet | May 5, 2019

ViiV Healthcare seeks FDA approval for long-term injectable HIV treatment

WRAL Tech Wire | April 29, 2019

Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591

NATAP | April 10, 2019

NATAP: HIV-Drug Resistance Testing/DHHS Guidelines

Last Updated: October 25, 2018

ViiV Healthcare Announces CHMP Positive Opinion for DOVATO® (DOLUTEGRAVIR/LAMIVUDINE) as a Once-Daily, Single-Pill, Two-Drug Reimen for the Treatment of HIV Infection

ViiV | April 26, 2019

New Rule at Centers for Medicare and Medicaid Helps Lower Costs of Meds

POZ | April 23, 2019

Special thanks to The AIDS Institute for leading the charge on this important issue

Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

NATAP | April 18, 2019

FDA Has Approved New Two-Drug Regimen to Treat People with HIV

Healthline | April 15, 2019

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks

Janssen | April 11, 2019

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

FDA | April 8, 2019

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases

Market Watch |  Apr 9, 2019

Pharma giant profits from HIV treatment funded by taxpayers and patented by the government

Washington Post | March 26, 2019

Gilead's Asegua Therapeutics selected to partner with health department for hepatitis C drug subscription model

Gilead | March 26, 2019

Long-acting injectable treatment maintains viral suppression

aidsmap | March 8, 2019

Factors associated with therapeutic failure of 2-drug regimens, DAT’AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable

Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2019, Seattle

Integrase inhibitor treatment leads to greater weight gain

aidsmap | March 7, 2019

ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection

ViiV | March 7, 2019

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy

AIDS: March 1, 2019

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Gilead | February 11, 2019

Acyclovir labeling now includes details for treating premature infants infected with herpes virus

NIH | February 8, 2019

FDA Hepatitis Update- VEMLIDY labeling revised (renal information)

FDA | February 6, 2019

U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate)
Merck | January 22, 2019

Pharm To Exam Table – Candida glabrata Urinary Tract Infections

University of Nebraska Medical Center | December 21, 2018

Note from Dr. Reznik – This information is valuable for oral infections with Candida glabrata


FDA | December 11, 2018

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

The Lancet | November 9, 2018

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov

FDA HIV Update: GENVOYA, STRIBILD, and TYBOST Pregnancy Label

FDA | November 7, 2018

Novel antibiotic shows promise in treatment of uncomplicated gonorrhea

NIH | November 7, 2018

NASTAD Announces the Release of PrEPcost.org

NASTAD | November 6, 2018

Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)

NATAP | November 6, 2018

Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than ...

aidsmap | November 2018

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant patients ...

aidsmap | November 2, 2018

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

aidsmap | November 1, 2018

FDA HIV Update- ODEFSEY/COMPLERA: Pregnancy Label Updates

FDA | October 31, 2018

ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Two Thirds Reach Sub-50 Viral Load Through 48 Weeks With Ibalizumab

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Polypharmacy in One Third of Big HIV Cohort vs One Fifth of Non-HIV Group
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Good HIV Response Rate, Sustained Safety Through 96 Weeks With D/C/F/TAF
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Outcomes of Patients Not Achieving Primary Endpoint From an Ibalizumba Phase 3 Trial

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Bictegravir/F/TAF Noninferior to DTG Plus F/TAF at 96 Weeks: No Resistance
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow